Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Zhang, Lixia ^a   Su, Yuanbo ^a   Hsieh, Evelyn ^a   Xia, Weibo ^a   Xie, Jing ^a   Han, Yang ^a   Cao, Ying ^a   Li, Yanling ^a   Song, Xiaojing ^a   Zhu, Ting ^a   Li, Taisheng ^a   Yu, Wei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Bone mineral density (BMD); Bone turnover marker (BTM); Highly active antiretroviral therapy (HAART)

Indexed keywords

25 HYDROXYVITAMIN D; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; LAMIVUDINE; NEVIRAPINE; PARATHYROID HORMONE; PROCOLLAGEN C PROTEINASE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUMBAR SPINE; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; ADVERSE EFFECTS; ASIAN CONTINENTAL ANCESTRY GROUP; BONE REMODELING; DRUG EFFECTS; ETHNOLOGY; FOLLOW UP; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE REMODELING; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84880962125     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-224     Document Type: Article

References (44)

1. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, Fraenkel L, Mattocks K, Rimland D, Rodriguez-Barradas MC, et al. PLoS One 2011 6 17217 10.1371/journal.pone.0017217 21359191
2. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. Triant VA, Brown TT, Lee H, Grinspoon SK, J Clin Endocrinol Metab 2008 93 3499 3504 10.1210/jc.2008-0828
3. Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal. Cournil A, Eymard-Duvernay S, Diouf A, Moquet C, Coutherut J, Ngom GN, Cames C, Taverne B, Bork K, Sow PS, et al. PLoS One 2012 7 31726 10.1371/journal.pone.0031726
4. The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients. Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS, Zhonghua Nei Ke Za Zhi 2010 49 649 652 20979781
5. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. Brown TT, Qaqish RB, AIDS 2006 20 2165 2174 10.1097/QAD.0b013e32801022eb (Pubitemid 44684707)
6. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper DA, Carr A, J Infect Dis 2009 200 1746 1754 10.1086/644785
7. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE, J Infect Dis 2011 203 1791 1801 10.1093/infdis/jir188
8. Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2) vitamin D in HIV-positive patients after the initiation of tenofovir/ emtricitabine with atazanavir/ritonavir or efavirenz. Foca E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, et al. BMC Infect Dis 2012 12 38 10.1186/1471-2334-12-38
9. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, et al. Clin Infect Dis 2010 51 963 972 10.1086/656417
10. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, Stracke H, Bretzel RG, J Infect 2003 46 221 227 10.1053/jinf.2002.1109 (Pubitemid 36758180)
11. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R, AIDS Res Ther 2010 7 40 10.1186/1742-6405-7-40
12. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. Childs K, Welz T, Samarawickrama A, Post FA, AIDS 2012 26 253 262 10.1097/QAD.0b013e32834f324b
13. Evaluation of Vitamin D Levels among HIV-Infected Patients in New York City. Kim JH, Gandhi V, Psevdos G, Espinoza F, Park J, Sharp V, AIDS Res Hum Retroviruses 2012 28 235 241 10.1089/aid.2011.0040
14. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, Bush T, Brooks JT, Clin Infect Dis 2011 52 396 405 10.1093/cid/ciq158
15. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. Van Den Bout-Van DBC, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, Burger DM, Bravenboer B, Koopmans PP, Van Der Ven AJ, AIDS Res Hum Retroviruses 2008 24 1375 1382 10.1089/aid.2008. 0058
16. The pilot study of DXA assessment in chinese HIV-infected men with clinical lipodystrophy. Yao J, Yu W, Li T, Luo L, Lin Q, Tian J, Chang Y, J Clin Densitom 2011 14 58 62 10.1016/j.jocd.2010.08.002
17. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. Wang J, Kou H, Fu Q, Han Y, Qiu Z, Zuo L, Li Y, Zhu Z, Ye M, Ma Q, et al. PLoS One 2011 6 26739 10.1371/journal.pone.0026739
18. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME, Clin Pharmacokinet 2003 42 599 605 10.2165/00003088-200342060-00009 (Pubitemid 36805618)
19. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. Yin MT, McMahon DJ, Ferris DC, Zhang CA, Shu A, Staron R, Colon I, Laurence J, Dobkin JF, Hammer SM, et al. J Clin Endocrinol Metab 2010 95 620 629 10.1210/jc.2009-0708
20. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, Bollerslev J, Froland SS, J Clin Endocrinol Metab 1999 84 145 150 10.1210/jc.84.1.145 (Pubitemid 29036693)
21. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Serrano S, Marinoso ML, Soriano JC, Rubies-Prat J, Aubia J, Coll J, Bosch J, Del RL, Vila J, Goday A, et al. Bone 1995 16 185 191 10.1016/8756-3282(94)00028-X
22. Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Fang J, Freeman R, Jeganathan R, Alderman MH, Ethn Dis 2004 14 280 284 (Pubitemid 39302871)
23. Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. Silverman SL, Madison RE, Am J Public Health 1988 78 1482 1483 10.2105/AJPH.78.11.1482 (Pubitemid 18259694)
24. A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians. Ross PD, Norimatsu H, Davis JW, Yano K, Wasnich RD, Fujiwara S, Hosoda Y, Melton LR, Am J Epidemiol 1991 133 801 809
25. Application of high-resolution skeletal imaging to measurements of volumetric BMD and skeletal microarchitecture in Chinese-American and white women: explanation of a paradox. Walker MD, McMahon DJ, Udesky J, Liu G, Bilezikian JP, J Bone Miner Res 2009 24 1953 1959 10.1359/jbmr.090528
26. Vitamin D status and markers of bone turnover in Caucasian and South Asian postmenopausal women living in the UK. Lowe NM, Mitra SR, Foster PC, Bhojani I, McCann JF, Br J Nutr 2010 103 1706 1710 10.1017/S0007114509993850
27. Ethnic differences in levels of bone and cartilage biomarkers and hormonal responsiveness in nine groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. Holinka CF, Christiansen C, Tian XW, Ausmanas MK, Climacteric 2008 11 44 54 10.1080/13697130701744886
28. Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Eastell R, Garnero P, Audebert C, Cahall DL, Bone 2012 50 1141 1147 10.1016/j.bone.2012.02.003
29. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. Piso RJ, Rothen M, Rothen JP, Stahl M, J Acquir Immune Defic Syndr 2011 56 320 324 10.1097/QAI.0b013e31820cf010
30. Potential predictive factors of osteoporosis in HIV-positive subjects. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, Bini T, Sardanelli F, Cornalba G, Monforte A, Bone 2006 38 893 897 10.1016/j.bone.2005. 11.001 (Pubitemid 44500653)
31. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tanko LB, Eur J Clin Pharmacol 2006 62 781 792 10.1007/s00228-006- 0174-3 (Pubitemid 44521426)
32. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD, J Bone Miner Res 1999 14 1614 1621 10.1359/jbmr.1999.14.9.1614 (Pubitemid 29416689)
33. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. Dolan SE, Kanter JR, Grinspoon S, J Clin Endocrinol Metab 2006 91 2938 2945 10.1210/jc.2006-0127 (Pubitemid 44271739)
34. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J, HIV Clin Trials 2007 8 164 172 10.1310/hct0803-164 (Pubitemid 47121761)
35. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J, Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J, HIV Med 2011 12 157 165 10.1111/j.1468-1293.2010.00864.x
36. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, Da SB, J Acquir Immune Defic Syndr 2009 51 554 561 10.1097/QAI.0b013e3181adce44
37. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, AIDS 2009 23 817 824
38. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, Mira JA, Corzo JE, Gomez-Mateos J, Rueda A, Sanchez-Burson J, et al. HIV Clin Trials 2003 4 337 346 10.1310/4X0H-UVMJ-BHYW-CPFB (Pubitemid 37304437)
39. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Brown TT, Ross AC, Storer N, Labbato D, McComsey GA, Antivir Ther 2011 16 1063 1072 10.3851/IMP1874
40. Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study. Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW, J Clin Endocrinol Metab 2013 98 1659 1666 10.1210/jc.2012-3686
41. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. Adeyemi OM, Agniel D, French AL, Tien PC, Weber K, Glesby MJ, Villacres MC, Sharma A, Merenstein D, Golub ET, et al. J Acquir Immune Defic Syndr 2011 57 197 204 10.1097/QAI.0b013e31821ae418
42. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. Haug C, Muller F, Aukrust P, Froland SS, J Infect Dis 1994 169 889 893 10.1093/infdis/169.4.889 (Pubitemid 24102128)
43. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Ross AC, Judd S, Kumari M, Hileman C, Storer N, Labbato D, Tangpricha V, McComsey GA, Antivir Ther 2011 16 555 563 10.3851/IMP1784
44. Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study (WIHS) participants with advanced disease on HAART. Aziz AM, Livak B, Burke-Miller J, French A, Glesby MJ, Sharma A, Young M, Villacres M, Tien PC, Golub E, et al. Aids 2013 27 573 578 10.1097/QAD.0b013e32835b9ba1